President Donald Trump's nomination of Kevin Warsh to lead the Federal Reserve sets the stage for a potential pivot in U.S. monetary policy, placing a seasoned yet controversial figure with deep Wall Street ties at the helm.
Despite posting robust quarterly earnings, Microsoft shares tumbled over 10% as investors balked at rising costs and a cautious outlook, raising questions about the sustainability of its AI-driven growth narrative.
Exclusive footage and soldier testimonies reveal a disturbing pattern within Russian ranks: wounded amputees, including former prisoners, are being ordered back into combat as casualties mount and manpower dwindles.
Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
Secretary-General Antonio Guterres warns in a confidential letter that the United Nations faces a severe cash crunch, driven by unpaid dues and restrictive budget rules, threatening its operational viability by mid-year.
With the specter of U.S. military action looming, Iran is engaging in a frantic diplomatic push with regional powers like Turkey, while global capitals scramble to prevent a full-scale war. Despite the outreach, analysts warn the window for de-escalation is narrowing.
The Kremlin confirmed Friday that President Vladimir Putin has agreed to a week-long pause in strikes on the Ukrainian capital Kyiv, a move initiated by a personal request from U.S. President Donald Trump. The temporary ceasefire, set to expire Sunday, comes amid a brutal cold snap and ahead of a new round of negotiations.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.
Analysts at BTIG have upgraded mortgage REIT Annaly Capital Management (NLY) from 'Neutral' to 'Buy', with a $25 price target, arguing the stock is positioned to benefit from dividend stability and potential spread movements in a turbulent interest rate landscape.
UBS initiates coverage on Rithm Capital with a Buy rating and a $16 price target, highlighting the REIT's aggressive acquisition strategy—including the purchases of Paramount Group and Crestline—as a key driver for expanding its asset management footprint and unlocking shareholder value.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Iran's foreign minister stated readiness for 'fair' negotiations with Washington but firmly ruled out discussing its defense capabilities, as regional powers intensify diplomacy to avert a military confrontation.
Truist Securities has slightly lowered its price target on Tesla shares to $438, citing the significant capital expenditure required for the automaker's aggressive shift towards AI and robotics, despite a solid Q4 performance.
Investment firm TD Cowen has increased its price target on Tesla (TSLA) to $519, maintaining a Buy rating. The adjustment follows a fourth-quarter performance marked by strong margins and progress on autonomous driving projects, though tempered by higher capital expenditure forecasts and vague timelines for full self-driving technology.
Analysts at Truist Securities have adjusted their outlook for Packaging Corporation of America (PKG), lowering the price target to $270 following a fourth-quarter earnings miss. Despite the revision, the firm reiterates its Buy rating, suggesting the recent stock dip may present a strategic buying opportunity ahead of anticipated strength in the packaging sector.
